Erasca (ERAS) News Today → Must-See: Elon’s New Invention is Absolutely Insane (From InvestorPlace) (Ad) Free ERAS Stock Alerts $1.97 +0.12 (+6.49%) (As of 05/17/2024 08:53 PM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 17 at 2:29 PM | msn.comErasca stock climbs 10% amid pipeline restructuring, equity offeringMay 16, 2024 | globenewswire.comErasca Announces Strategic In-Licensing of RAS-Targeting FranchiseMay 16, 2024 | globenewswire.comErasca Announces Pricing of Underwritten Offering of Common StockMay 14, 2024 | markets.businessinsider.comErasca’s Stable Cash Runway and Upcoming Clinical Milestones Secure Buy RatingMay 14, 2024 | americanbankingnews.comComparing Journey Medical (NASDAQ:DERM) & Erasca (NASDAQ:ERAS)May 13, 2024 | americanbankingnews.comHC Wainwright Reiterates "Buy" Rating for Erasca (NASDAQ:ERAS)May 9, 2024 | marketbeat.comErasca's (ERAS) "Buy" Rating Reaffirmed at HC WainwrightHC Wainwright restated a "buy" rating and set a $8.00 price target on shares of Erasca in a report on Thursday.May 9, 2024 | investorplace.comERAS Stock Earnings: Erasca Misses EPS for Q1 2024May 8, 2024 | globenewswire.comErasca Reports First Quarter 2024 Business Updates and Financial ResultsMay 7, 2024 | finance.yahoo.comErasca to Present at the Bank of America Health Care ConferenceMay 1, 2024 | marketbeat.comErasca, Inc. (NASDAQ:ERAS) Sees Large Increase in Short InterestErasca, Inc. (NASDAQ:ERAS - Get Free Report) saw a significant increase in short interest during the month of April. As of April 15th, there was short interest totalling 9,480,000 shares, an increase of 6.9% from the March 31st total of 8,870,000 shares. Approximately 10.6% of the shares of the company are short sold. Based on an average daily volume of 783,400 shares, the short-interest ratio is presently 12.1 days.April 24, 2024 | globenewswire.comErasca Announces Three Presentations at the 2024 ASCO Annual MeetingApril 16, 2024 | finance.yahoo.comInstitutional investors may adopt severe steps after Erasca, Inc.'s (NASDAQ:ERAS) latest 11% drop adds to a year lossesApril 9, 2024 | fool.comErasca (NASDAQ: ERAS)April 3, 2024 | markets.businessinsider.comErasca’s Promising Naporafenib Data and Financial Stability Merit a Buy RatingApril 2, 2024 | marketbeat.comErasca, Inc. (NASDAQ:ERAS) Short Interest Down 8.9% in MarchErasca, Inc. (NASDAQ:ERAS - Get Free Report) was the target of a large decrease in short interest in March. As of March 15th, there was short interest totalling 9,020,000 shares, a decrease of 8.9% from the February 29th total of 9,900,000 shares. Based on an average daily trading volume, of 801,900 shares, the short-interest ratio is presently 11.2 days. Approximately 10.1% of the shares of the stock are short sold.April 2, 2024 | marketbeat.comThe Goldman Sachs Group Boosts Erasca (NASDAQ:ERAS) Price Target to $7.00The Goldman Sachs Group lifted their price target on Erasca from $6.00 to $7.00 and gave the stock a "buy" rating in a research report on Tuesday.April 1, 2024 | finance.yahoo.comErasca, Inc. (NASDAQ:ERAS) Q4 2023 Earnings Call TranscriptMarch 31, 2024 | seekingalpha.comErasca, Inc. (ERAS) R&D Update Call and Q4 2023 Earnings Call TranscriptMarch 29, 2024 | finanznachrichten.deErasca, Inc.: Erasca Reports Fourth Quarter 2023 and Full Year 2023 Business Updates and Financial ResultsMarch 29, 2024 | finance.yahoo.comErasca Inc (ERAS) Aligns with EPS Projections, Reveals Robust Balance Sheet and Key Clinical ...March 29, 2024 | markets.businessinsider.comErasca’s Strong Clinical Data and Enhanced Financial Position Support Buy RatingMarch 28, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Celcuity (CELC) and Erasca (ERAS)March 28, 2024 | msn.comErasca to get $45M funding via private placementMarch 28, 2024 | marketwatch.comErasca Shares Climb After 4Q Loss Narrows, $45 Million Private PlacementMarch 27, 2024 | investorplace.comERAS Stock Earnings: Erasca Beats EPS for Q4 2023March 27, 2024 | globenewswire.comErasca Announces $45 Million Oversubscribed Private Placement FinancingMarch 27, 2024 | globenewswire.comErasca Reports Fourth Quarter 2023 and Full Year 2023 Business Updates and Financial ResultsMarch 21, 2024 | msn.comOcugen hits a 52-week high after decision to lower quorum requirementFebruary 27, 2024 | finance.yahoo.comERAS Mar 2024 2.000 putFebruary 17, 2024 | finance.yahoo.comERAS Mar 2024 2.500 callFebruary 15, 2024 | msn.comErasca collaborates with Novartis on cancer therapy trialsFebruary 14, 2024 | finance.yahoo.comErasca Announces Two Clinical Trial Collaboration and Supply Agreements for Trametinib to Evaluate Naporafenib Combination in SEACRAFT-1 and SEACRAFT-2 TrialsFebruary 1, 2024 | finance.yahoo.comErasca to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology ConferenceJanuary 9, 2024 | finance.yahoo.comIs Erasca (NASDAQ:ERAS) In A Good Position To Invest In Growth?January 7, 2024 | benzinga.comErasca Stock (NASDAQ:ERAS), Analyst Ratings, Price Targets, PredictionsJanuary 6, 2024 | msn.comB of A Securities Downgrades Erasca (ERAS)January 3, 2024 | finance.yahoo.comErasca to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceJanuary 2, 2024 | marketbeat.comShort Interest in Erasca, Inc. (NASDAQ:ERAS) Grows By 21.4%Erasca, Inc. (NASDAQ:ERAS - Get Free Report) was the target of a significant increase in short interest in December. As of December 15th, there was short interest totalling 10,990,000 shares, an increase of 21.4% from the November 30th total of 9,050,000 shares. Approximately 11.9% of the shares of the stock are sold short. Based on an average daily volume of 1,140,000 shares, the short-interest ratio is currently 9.6 days.December 13, 2023 | markets.businessinsider.comStrong Buy Rating for Erasca’s Stock on FDA Fast Track Designation and Market Expansion PotentialDecember 13, 2023 | finance.yahoo.comErasca Co-Founder Acquires 3.2% More StockDecember 11, 2023 | markets.businessinsider.comErasca: FDA Grants Fast Track Designation To Naporafenib In Combination With TrametinibDecember 11, 2023 | finance.yahoo.comErasca Granted FDA Fast Track Designation for Pan-RAF Inhibitor Naporafenib in Patients with Advanced NRAS-Mutated MelanomaDecember 7, 2023 | msn.comErasca director Alexander Casdin discloses purchase of 30K sharesDecember 7, 2023 | msn.comErasca CEO Lim buys stock worth $1.7M - filingNovember 28, 2023 | finanznachrichten.deErasca, Inc.: Erasca Achieves Key Milestones for Naporafenib and ERAS-801 Programs and Extends Cash RunwayNovember 28, 2023 | finance.yahoo.comErasca Achieves Key Milestones for Naporafenib and ERAS-801 Programs and Extends Cash RunwayNovember 9, 2023 | msn.comErasca GAAP EPS of -$0.20 beats by $0.01November 9, 2023 | finance.yahoo.comErasca Reports Third Quarter 2023 Financial Results and Business UpdatesNovember 8, 2023 | morningstar.comErasca Inc ERAS Get Erasca News Delivered to You Automatically Sign up to receive the latest news and ratings for ERAS and its competitors with MarketBeat's FREE daily newsletter. Email Address Must-See: Elon’s New Invention is Absolutely Insane (Ad)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street veteran, Eric Fry… This mind-blowing new technology could be bigger than the iPhone. Click here for the full story… ERAS Media Mentions By Week ERAS Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ERAS News Sentiment▼0.180.42▲Average Medical News Sentiment ERAS News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ERAS Articles This Week▼51▲ERAS Articles Average Week Get Erasca News Delivered to You Automatically Sign up to receive the latest news and ratings for ERAS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Black Diamond Therapeutics News Nektar Therapeutics News Atai Life Sciences News Nkarta News Kamada News Mersana Therapeutics News ADC Therapeutics News Verastem News Atea Pharmaceuticals News UroGen Pharma News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ERAS) was last updated on 5/20/2024 by MarketBeat.com Staff From Our PartnersShocking: One AI startup's revenue could surge 4,735%Manward PressThe Overlooked Retirement Asset You Probably Don’t OwnCrypto 101 MediaNext President (Not Trump. Not Biden.)The Freeport SocietyUrgent Nvidia WarningAltimetryElon’s New Device is About to Shock the WorldInvestorPlace"The Biggest Drug Ever" Is ComingBehind the MarketsCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingExposed: 10 CENT Crypto to Explode May 20th?True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Erasca, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
